Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

The Effect of Levosimendan on Pulmonary Artery Pressure and Right Ventricular Function in the Perioperative Period in Patients With CTEPH After Pulmonary Thromboendarterectomy (LEVO-CTEPH)

The Effect of Levosimendan on Pulmonary Artery Pressure and Right Ventricular Function in the Perioperative Period in Patients With CTEPH After Pulmonary Thromboendarterectomy: a Single-center Pilot Prospective Randomized Placebo-controlled Double-blind Clinical Trial

A single-center pilot prospective randomized placebo-controlled double-blind clinical trial.

Study objective - to investigate the efficacy and safety of levosimendan in patients in the perioperative period following pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension (CTEPH).

Research Objectives:

  1. To assess the impact of levosimendan administration on pulmonary artery pressure during the perioperative period in patients who have undergone pulmonary endarterectomy for CTEPH.
  2. To evaluate the effect of levosimendan administration on right ventricular function parameters during the perioperative period in patients after pulmonary endarterectomy for CTEPH.
  3. To determine the influence of levosimendan on the need for inotropic and vasopressor support (VIS) during the perioperative period in patients following pulmonary endarterectomy for CTEPH.
  4. To examine the effect of levosimendan on the clinical course and complications during the postoperative period in patients after pulmonary endarterectomy for CTEPH.
  5. To evaluate the cardioprotective effect of levosimendan in patients following pulmonary endarterectomy for CTEPH.
  6. To assess the impact of levosimendan on in-hospital mortality in patients after pulmonary endarterectomy for CTEPH.

Panoramica dello studio

Descrizione dettagliata

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and severe form of pulmonary hypertension resulting from thrombotic obstruction of the pulmonary arteries. It is typically a late complication of acute pulmonary embolism. The incidence of CTEPH has been reported to reach 13 cases per million population per year.

Organized thrombotic masses cause stenosis or obstruction of the pulmonary arteries, leading to increased pulmonary artery pressure and pulmonary vascular resistance. This results in redistribution of pulmonary blood flow, microangiopathy, and remodeling of small-caliber pulmonary vessels. Pulmonary endarterectomy (PEA) is the recommended standard of care for patients with CTEPH and can be curative. In experienced centers, mortality rates are less than 5%.

Residual pulmonary hypertension after PEA, defined as a mean pulmonary artery pressure ≥25 mmHg, occurs in 17-51% of patients. This complication is associated with residual thrombotic material in distal pulmonary arteries and small-vessel disease. Severe pulmonary hypertension causes right ventricular maladaptive remodeling and dysfunction, ultimately leading to right ventricular failure, which is the most important determinant of survival and quality of life. Residual pulmonary hypertension negatively affects long-term survival, with higher mortality associated with mean pulmonary artery pressure ≥36 mmHg and pulmonary vascular resistance ≥416 dyn·s·cm-⁵.

Currently, a multimodal approach to CTEPH is being considered. Surgery addresses the primary component by removing thrombotic masses, but pharmacotherapy is required for the microvascular component and persistently elevated pulmonary artery pressure. Targeted therapies are costly, and their benefit remains unclear. Clinical guidelines currently recommend only symptomatic therapy for patients with residual pulmonary hypertension and right ventricular failure after PEA, and no optimal treatment strategy has been defined for this complication in the early postoperative period.

Rationale for Levosimendan: Levosimendan has shown promising effects in pulmonary hypertension and right ventricular failure. Its mechanism of action involves opening ATP-dependent potassium channels in vascular smooth muscle cells, leading to vasodilation and reduction of both preload and afterload. Additionally, levosimendan binds to cardiac troponin C, increasing myofibril contractility. Previous studies have demonstrated that levosimendan reduces pulmonary artery pressure and pulmonary vascular resistance, improves right ventricular function (including increased TAPSE, ejection fraction, and cardiac output), and suppresses smooth muscle cell proliferation in pulmonary arteries. However, no studies to date have investigated the effect of levosimendan in patients with CTEPH undergoing pulmonary endarterectomy, and the drug has not previously been used in the perioperative management of this patient population.

Study objective is to evaluate the effect of levosimendan on pulmonary artery pressure and right ventricular function in patients undergoing pulmonary endarterectomy for CTEPH.

Tipo di studio

Interventistico

Iscrizione (Stimato)

50

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Novosibirsk, Russia, 630055
        • Reclutamento
        • Meshalkin Research Institute of Pathology of Circulation

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Voluntary signed informed consent to participate in the study
  • Scheduled for pulmonary thromboendarterectomy surgery
  • Aged ≥18 years

Exclusion Criteria :

  • Patient refusal
  • Language barrier preventing understanding of the study
  • Severe renal failture (creatinine clearance <30 mL/min)
  • Severe hepatic insufficiency (Child-Pugh score >9 points)
  • Participation in other clinical trials
  • History of allergic reaction to levosimendan, Soluvit, or any of their components
  • Use of levosimendan within 30 days prior to screening

Discontinuation Criteria (or Withdrawal Criteria):

  • Need for extracorporeal membrane oxygenation (ECMO) support during the perioperative period
  • Pulmonary hemorrhage during the perioperative period

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Levosimendan

A levosimendan infusion after induction of anesthesia.

Infusion of levosimendan will be initiated after the induction of anesthesia, discontinued at the onset of patient cooling, and resumed at the time of rewarming at 34°C. The drug will be administered using an infusion pump as a continuous infusion at a rate of 0.1 mcg/kg/min. The duration of the drug infusion will be up to 48 hours.

Preoperative management will be conducted according to the patients' primary and concomitant diseases.

Comparatore placebo: "Soluvit"

A placebo infusion after induction of anesthesia.

Patients in the placebo group will receive an equivalent amount of a colored solution of Soluvit.Soluvit (ATC B05XC; a yellow vitamin mixture indistinguishable from the investigational drug, levosimendan).

Preoperative management will be conducted according to the patients' primary and concomitant diseases.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Mean pulmonary artery pressure (mPAP)
Lasso di tempo: 24 hours at the end of surgery

Mean pulmonary artery pressure (mPAP) measured 24 hours after the end of surgery

24 hours at the end of surgery

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pulmonary Vascular Resistance (PVR)
Lasso di tempo: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Pulmonary vascular resistance

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Pulmonary Artery Pulsatility Index (PAPI)
Lasso di tempo: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Pulmonary artery pulsatility index. PAPi = (PASP - PADP) / RAP (PASP - PADP): Pulmonary Artery Pulse Pressure. This is the difference between the pressure in the pulmonary artery when the heart contracts (systolic) and relaxes (diastolic).

RAP: Right Atrial Pressure.

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Pulmonary Artery Pressure (PAP)
Lasso di tempo: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Pulmonary artery pressure

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Arterial Blood Pressure (ABP)
Lasso di tempo: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Arterial blood pressure

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Central Venous Pressure (CVP)
Lasso di tempo: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Central venous pressure

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Cardiac Index (CI)
Lasso di tempo: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Cardiac index

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Systemic Vascular Resistance (SVR)
Lasso di tempo: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Systemic vascular resistance

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Right Ventricular Stroke Work Index (RVSWI)
Lasso di tempo: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Right ventricular stroke work index

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Pulmonary Capillary Wedge Pressure (PAWP)
Lasso di tempo: • before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery

Pulmonary capillary wedge pressure

• before skin incision • at the end of surgery • 4 hours after of surgery • 24 hours after of surgery • 48 hours after of surgery • 72 hours after of surgery
Ejection fraction
Lasso di tempo: • before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery

Ejection fraction (EF) of both the right and left ventricles (LVEF and RVEF)

• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
Right Ventricular End-Diastolic Volume (RVEDV)
Lasso di tempo: • before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery

Right ventricular end diastolic volume

• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
Right Ventricular systolic pressure (RVSP)
Lasso di tempo: • before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery

Right ventricular systolic pressure

• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
Fractional area change (FAC) of the right ventricle
Lasso di tempo: • before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery

Fractional area change (FAC) of the right ventricle

• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
Tricuspid annular plane systolic excursion (TAPSE)
Lasso di tempo: • before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery

Tricuspid annular plane systolic excursion

• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
Right ventricular free-wall longitudinal strain (RV FW LS)
Lasso di tempo: • before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery

Right ventricular free-wall longitudinal strain

• before skin incision • at the end of surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
Quantitative troponin I level
Lasso di tempo: • before skin incision• 24 hours after the end of surgery• 48 hours after surgery

Quantitative concentration of troponin I

• before skin incision• 24 hours after the end of surgery• 48 hours after surgery
Vasoactive Inotropic Support
Lasso di tempo: • before skin incision • at the end of surgery • 4 hours after surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery

In the perioperative period, the Vasoactive-Inotropic Score (VIS) will be calculated using the following formula:

VIS = dobutamine (mcg/kg/min) + dopamine (mcg/kg/min) + (100 × epinephrine (mcg/kg/min) + (100 × norepinephrine (mcg/kg/min)) + (10 × milrinone (mcg/kg/min))

• before skin incision • at the end of surgery • 4 hours after surgery • 24 hours after surgery • 48 hours after surgery • 72 hours after surgery
Residual Pulmonary Hypertension
Lasso di tempo: From the end of surgery up to 72 hours postoperatively

Number of participants with residual pulmonary hypertension, defined as postoperative mean pulmonary artery pressure (mPAP) > 25 mm Hg, measured by right heart catheterization in the postoperative period (up to 72 hours after surgery).

From the end of surgery up to 72 hours postoperatively
Incidence of reperfusion pulmonary edema
Lasso di tempo: From the end of surgery up to 72 hours postoperatively

Number of participants who develop pulmonary edema within 24 hours following pulmonary endarterectomy (PEA), confirmed by chest X-ray or chest CT and clinical criteria (including dyspnea, hypoxemia, and bilateral infiltrates), characterized by the presence of frothy secretions in the endotracheal tube (ETT), asymmetric opacities on chest X-ray, and an oxygenation index (PaO₂/FiO₂) < 300 mm Hg in the early postoperative period (up to 72 hours)

From the end of surgery up to 72 hours postoperatively
Incidence of cardiac arrhythmias
Lasso di tempo: 30 days

Proportion of participants who develop any new-onset cardiac arrhythmia (including atrial fibrillation/flutter, ventricular tachycardia) during the study period, as documented by 12-lead ECG or continuous cardiac monitoring.

30 days
Cardiovascular events: myocardial infarction or stroke
Lasso di tempo: 30 days

Number of participants with cardiovascular events, defined as myocardial infarction (MI) or stroke (cerebrovascular accident, CVA), occurring during the postoperative period.Myocardial infarction is defined according to the Fourth Universal Definition of Myocardial Infarction (elevated cardiac troponin with at least one of the following: ischemic symptoms, new ischemic ECG changes, or imaging evidence of new loss of viable myocardium). Stroke is defined as an acute episode of focal or global neurological dysfunction caused by infarction or hemorrhage in the brain, spinal cord, or retina, confirmed by neuroimaging (CT or MRI).

30 days
Respiratory Complications: Pneumothorax
Lasso di tempo: 30 days

Number of participants with postoperative pneumothorax, defined as the presence of air in the pleural cavity, confirmed by chest X-ray or chest CT, occurring during the postoperative period.

30 days
Neurological Complications: Seizures
Lasso di tempo: From enrollment to the end of treatment at 30 days

Number of participants with postoperative seizures, defined as a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. Diagnosis is based on clinical assessment and, when available, confirmed by electroencephalography (EEG).

From enrollment to the end of treatment at 30 days
Renal complications: acute kidney injury (AKI) according to KDIGO criteria
Lasso di tempo: 30 days

Number of participants with postoperative acute kidney injury (AKI), defined and staged according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria, occurring during the early postoperative period (up to 48 hours after surgery). AKI is defined as any of the following: increase in serum creatinine by ≥ 0.3 mg/dL (≥ 26.5 μmol/L) within 48 hours; or increase in serum creatinine to ≥ 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or urine output < 0.5 mL/kg/hour for 6 hours. AKI is staged as follows: Stage 1 (serum creatinine 1.5-1.9 times baseline or ≥ 0.3 mg/dL increase, or urine output < 0.5 mL/kg/hour for 6-12 hours), Stage 2 (serum creatinine 2.0-2.9 times baseline, or urine output < 0.5 mL/kg/hour for ≥ 12 hours), and Stage 3 (serum creatinine ≥ 3.0 times baseline, or increase to ≥ 4.0 mg/dL, or initiation of renal replacement therapy, or urine output < 0.3 mL/kg/hour for ≥ 24 hours, or anuria for ≥ 12 hours).

30 days
Renal replacement therapy (RRT)
Lasso di tempo: From enrollment to the end of treatment at 30 days

Number of participants who require renal replacement therapy (RRT) in the early postoperative period

From enrollment to the end of treatment at 30 days
Use of inhaled nitric oxide (NO) and/or iloprost
Lasso di tempo: 30 days

Number of participants requiring administration of inhaled nitric oxide (NO) and/or inhaled iloprost in the postoperative period. for the management of residual pulmonary hypertension or right ventricular dysfunction. This includes administration as monotherapy or in combination

30 days
Blood transfusion
Lasso di tempo: 30 days

Number of participants requiring perioperative blood transfusion, including packed red blood cells (PRBCs), fresh frozen plasma (FFP), platelet concentrates, or cryoprecipitate, in the postoperative period. Transfusion requirements will be recorded as the number of participants receiving any transfusion.

30 days
Inotropic/vasopressor support
Lasso di tempo: From the end of surgery up to 72 hours postoperatively

Number of participants requiring postoperative inotropic and/or vasopressor support in the early postoperative period

From the end of surgery up to 72 hours postoperatively
Duration of mechanical ventilation (MV)
Lasso di tempo: 30 days

Total duration of invasive mechanical ventilation (MV) measured in hours (or days) from the time of intubation in the operating room or ICU until successful extubation. This includes the total time on the ventilator, both in the operating room and in the ICU, and includes any episodes of reintubation.

30 days
Duration of ICU stay
Lasso di tempo: 90 days

Total length of stay in the intensive care unit (ICU) measured in days from the time of admission to the ICU after surgery until discharge from the ICU to the general ward.

90 days
Duration of hospital stay
Lasso di tempo: 90 days

Total length of hospital stay measured in days

90 days
In-hospital mortality
Lasso di tempo: 90 days

yes/no

90 days

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

29 aprile 2025

Completamento primario (Stimato)

1 novembre 2027

Completamento dello studio (Stimato)

1 dicembre 2027

Date di iscrizione allo studio

Primo inviato

28 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

28 ottobre 2026

Primo Inserito (Effettivo)

4 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

4 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

28 ottobre 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Data sharing is not planned as this is a single-center study and institutional regulations do not permit sharing of individual patient data.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi